Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen
There is an urgent need to identify therapeutics for the treatment of Coronavirus disease 2019 (COVID-19). Although different antivirals are given for the clinical management of SARS-CoV-2 infection, their efficacy is still under evaluation. Here, we have screened existing drugs approved for human u...
Main Authors: | Jordi Rodon, Jordana Muñoz-Basagoiti, Daniel Perez-Zsolt, Marc Noguera-Julian, Roger Paredes, Lourdes Mateu, Carles Quiñones, Carles Perez, Itziar Erkizia, Ignacio Blanco, Alfonso Valencia, Víctor Guallar, Jorge Carrillo, Julià Blanco, Joaquim Segalés, Bonaventura Clotet, Júlia Vergara-Alert, Nuria Izquierdo-Useros |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-03-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2021.646676/full |
Similar Items
-
Plitidepsin: design, development, and potential place in therapy
by: Alonso-Álvarez S, et al.
Published: (2017-01-01) -
c-Jun N-Terminal Kinase Phosphorylation Is a Biomarker of Plitidepsin Activity
by: Alberto Muñoz, et al.
Published: (2013-05-01) -
Antibodies and Antibody Derivatives: New Partners in HIV Eradication Strategies
by: Jorge Carrillo, et al.
Published: (2018-10-01) -
SARS-CoV-2 Cellular Infection and Therapeutic Opportunities: Lessons Learned from Ebola Virus
by: Jordana Muñoz-Basagoiti, et al.
Published: (2021-01-01) -
Trabectedin and Plitidepsin: Drugs from the Sea that Strike the Tumor Microenvironment
by: Carlos M. Galmarini, et al.
Published: (2014-01-01)